title: 'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure.
abstract: The ongoing important debate about the relative benefits/risks of COX-1 or COX-2 NSAIDs is hampered by the use of a measure of 'selectivity' that is inherently flawed. An alternative measure provides more meaningful and clinically relevant information.
authors: Temple University School of Pharmacy, Philadelphia, PA, USA. robert.raffa@temple.edu.
authors: R B
authors: RB
authors: Raffa
authors: J A
authors: JA
authors: Gudin
authors: S
authors: S
authors: Nalamachu
authors: J V
authors: JV
authors: Pergolizzi
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics*; D015986:Confounding Factors, Epidemiologic; D051545:Cyclooxygenase 1 / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000378:metabolism; D006801:Humans; D020128:Inhibitory Concentration 50
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D051545:Cyclooxygenase 1